New investigations on retatrutide, a dual stimulant for incretin hormone and gastric inhibitory polypeptide, indicate promising findings in managing obesity and type 2 glucose intolerance. Initial evidence from clinical trials point to considerable reductions in body mass and enhanced glucose regulation. Ongoing examination is directed on long-term